Financial results for quarter and year ended on March 31, 2025

EBITDA margin expansionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.0%Reaction day

₹499.00

prior close

₹501.15

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-3.3% vs market

Medical Equipment & Supplies peers, median of 8sector-0.7%-2.3% vs sector

On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 2.3 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+2.6

15m

+3.8

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.0+0.3-3.3-0.7-2.3

Next day

-2.2+0.7-2.9-1.0-1.2

-2.5+1.0-3.5-0.1-2.4

-4.0+1.1-5.1+2.2-6.2

-4.2+0.8-5.0+0.5-4.7

-3.3+1.3-4.6-0.3-3.0

-0.6+1.7-2.3+0.5-1.1

15d

-4.6+1.5-6.1+1.5-6.1

-6.6+4.0-10.7-6.1-0.6

+7.4+1.8+5.6-3.6+11.0

+12.2-1.0+13.2-5.9+18.1

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 8Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Prevest Denpro Limited reported its audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Standalone revenue from operations rose about 8.5% year-on-year to Rs. 64.32 crore, while total income grew roughly 13% to Rs. 67.18 crore. Net profit increased around 13% to Rs. 18.20 crore (from Rs. 16.12 crore), lifting basic EPS to Rs. 15.16 from Rs. 13.44. The company continues to carry zero long-term debt, with cash and equivalents strengthening to Rs. 60.46 crore, and paid an increased dividend of Rs. 1.20 crore during the year. Statutory auditor Mittal & Associates issued an unmodified (clean) opinion on both standalone and consolidated results; the consolidated numbers include two wholly-owned subsidiaries, Denvisio Biomed Limited and Axiodent INC.

Likely market impact

Steady profit growth, a debt-free balance sheet with a rising cash pile, expanding margins and a higher dividend payout are positive signals for shareholders. However, revenue growth is in single digits, so the stock is likely to see a stable rather than a sharp move.